AU StockDetailed Quotes

Provided by Tiger Fintech (Singapore) Pte. Ltd.

IMUGENE LTD

0.040

+0.00514.29%

Volume:65.79M

Turnover:2.49M

Market Cap:298.30M

PE:-2.27

High:0.040

Open:0.037

Low:0.036

Close:0.035

Loading ...

Overview Company News Filings

ASX Market Open: Ever-extending US loss streak to bleed into red Friday – unless Oz bucks trend again | Jan 3, 2024

The Market Herald

5 worst ASX All Ordinaries shares of 2024

Imugene to Raise AU$46 Million in Convertible Notes, Warrants Issue

MT Newswires Live

Imugene Ltd - Issuance of Convertible Notes & Warrants for up to a$46M

THOMSON REUTERS

Imugene - Capital Raised to Be Used to Fund Co's Ongoing Clinical Trial Pipeline Including Azer-Cel, Others

THOMSON REUTERS

Imugene Ltd-Imugene Confirms Pending Receipt of C.$11M R&D Tax Refund

THOMSON REUTERS

6 ASX shares down 50%+ in 2024. Are they cheap?

ASX Market Update: Index retreats as Chinese stimulus disappoints | November 11, 2024

The Market Herald

Imugene Doses First Patient in Intratumoral Injection Group of Phase 1 Cancer Trial

MT Newswires Live

Imugene Opens Australian Site for Phase 1b Lymphoma Trial

MT Newswires Live

Why Imugene, Neuren, Sigma, and Smartgroup shares are charging higher

Imugene Says Bile Tract Cancer Patient Remains in Complete Response for Over Two Years in Early-Stage Trial

MT Newswires Live

Why Core Lithium, Imugene, Lifestyle Communities, and Mineral Resources shares are charging higher

Guess which ASX 300 stock is jumping 11% on big news

ASX Market Update: Gina Rinehart buys permits from Min Res in billion dollar deal | October 31, 2024

The Market Herald

2 All Ords ASX healthcare shares making BIG moves on quarterly updates

{"basename":"","ssrTDKData":{"titleTemplate":"%s - Tiger Brokers","title":"Tiger Brokers HK | Online Trading in stocks, bonds & ETFS","description":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","keywords":"tiger trading,tiger security,tiger broker hk,tigers co ltd,tiger trade hk,tiger brokers hk,stock broker,securities broker,online brokerage,hong kong broker,hk broker,online stock trading,online trading platform,stock trading platforms,trading application,stock trading,stock trading hong kong,buying stocks in hong kong,tiger brokers","social":{"ogDescription":"Discover Tiger Brokers HK, an online trading platform for stocks&ETFs, options&futures, bonds and crypto. Open an account to enjoy low commission trading today!","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.be62fbe1.png","ogUrl":"https://www.tigerhkgo.com/stock/IMU.AU/news?page=3"},"companyName":"Tiger Brokers"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"IMU.AU","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","market":"AU","secType":"STK","nameCN":"IMUGENE LTD","latestPrice":0.04,"timestamp":1742361120000,"preClose":0.035,"halted":0,"volume":65794805,"delay":0,"changeRate":0.142857,"change":0.005,"floatShares":6260580705,"shares":7457433979,"eps":-0.017588,"lyrEps":-0.021115,"pbRate":4.71,"amount":2490965,"amplitude":0.114286,"volumeRatio":2.5504411855664166,"dividePrice":0,"prevYearClose":0.037,"fiveDayClose":0.031,"twentyDayClose":0.039},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"IMU.AU\",,,,,undefined,":{"symbol":"IMU.AU","floatShares":6260580705,"roa":"-42.92%","roe":"-100.19%","lyrEps":-0.021115,"volumeRatio":2.5504411855664166,"shares":7457433979,"dividePrice":0,"high":0.04,"amplitude":0.114286,"preClose":0.035,"low":0.036,"week52Low":0.031,"pbRate":"4.71","psRate":"-162.15","week52High":0.112,"institutionHeld":0,"latestPrice":0.04,"eps":-0.017588,"divideRate":0,"volume":65794805,"delay":0,"ttmEps":-0.017588,"open":0.037,"prevYearClose":0.037,"prevWeekClose":0.036,"prevMonthClose":0.037,"prevQuarterClose":0.037,"fiveDayClose":0.031,"twentyDayClose":0.039,"sixtyDayClose":0.036},"@#url:\"https://hq.skytigris.cn/fundamental/corporate_actions/details/IMU.AU\",params:#limit:5,,,undefined,":[],"@#url:\"https://hq.skytigris.cn/fundamental/dividend/history\",params:#symbol:\"IMU.AU\",market:\"AU\",,,undefined,":[],"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"IMU.AU\",pageSize:16,pageCount:3,lang_content:\"en\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2500153490","title":"ASX Market Open: Ever-extending US loss streak to bleed into red Friday – unless Oz bucks trend again | Jan 3, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2500153490","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500153490?lang=en_us&edition=fundamental","pubTime":"2025-01-03 05:58","pubTimestamp":1735855080,"startTime":"0","endTime":"0","summary":"The ASX 200 is expected to open 0.07% lower at 8,185 points, though after yesterday’s defiant reversal things may change through morning trade.Futures tipping a drop Down Under comes after the S&P 500 and Nasdaq composite both extended their losing streaks to the longest seen in the U.S. since April – much of which seems to be investors taking profits.Impending U.S. economic data on CPI and payrolls may also be playing a role; fourth-quarter reporting will also be starting all across Wall Street from January 13.One docket that has stood out is Imugene Limited , with the HotCopper forum favourite dosing its first Aussie patient as it tests its Azer-Cel technology.The Australian Securities Exchange  has also declared today that it’s taking its crackdowns into hyperdrive as it keeps dealing with executives declaring company moves poorly – more fines will soon follow.That’s Market Open, I’m Isaac McIntyre, stick with us for HotCopper’s Market Close.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-open-2-2025-01-03/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["ASX.AU","IMU.AU","BK7039","BK7067","BK7508"],"gpt_icon":0},{"id":"2500520904","title":"5 worst ASX All Ordinaries shares of 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2500520904","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2500520904?lang=en_us&edition=fundamental","pubTime":"2025-01-03 05:00","pubTimestamp":1735851600,"startTime":"0","endTime":"0","summary":"S&P/ASX All Ordinaries Index  shares rose by 7.55% and delivered total gross returns, including dividends, of 11.44% last year.That's a pleasing overall market return in anyone's language.But for some stockpickers, it was a hard year.Investors in the following five ASX All Ordinaries shares endured a teeth-gritting 12 months in 2024.5 ASX All Ordinaries shares that plunged in value in 2024. Here are the five ASX All Ordinaries companies whose share prices declined the most in 2024.ASX All Ordinaries lithium share Liontown was the worst performer of the year in terms of price change.Patriot is the second lithium share comprising the five biggest losers of the ASX All Ordinaries in 2024.Investors were dismayed when nothing came of discussions with US lithium giantAlbemarle Corp last year. The companies ceased talks in May after spending nine months assessing partnership opportunities for a downstream lithium hydroxide plant for Patriot's Corvette Lithium Project in Canada.In November, Wi","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2025/01/03/5-worst-asx-all-ordinaries-shares-of-2024/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["LU2357305700.SGD","XAO.AU","LTR.AU","LU1244550221.USD","LU1974910355.USD","LU1244550577.SGD","LU1861219969.SGD","PMT.AU","SGR.AU","LU2106854487.HKD","LU1917777945.USD","BK4548","LU1720051108.HKD","ALB","BK4109","BK7067","BK7508","BK7078","LU2023250504.SGD","BK7507","BK4545","LU1548497426.USD","LU1720051017.SGD","LU1861214812.USD","BK4585","BK7506","WC8.AU","BK7095","LU2249611893.SGD","LU1878469433.USD","LU1803068623.USD","IMU.AU","LU1244550494.USD","BK4588","LU0823414478.USD","PLS.AU","BK7504"],"gpt_icon":1},{"id":"2493716748","title":"Imugene to Raise AU$46 Million in Convertible Notes, Warrants Issue","url":"https://stock-news.laohu8.com/highlight/detail?id=2493716748","media":"MT Newswires Live","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493716748?lang=en_us&edition=fundamental","pubTime":"2024-12-24 05:58","pubTimestamp":1734991104,"startTime":"0","endTime":"0","summary":"Imugene  will raise AU$46 million via the issue of notes and warrants to investor CVI Investments, according to a Monday filing with the Australian bourse.The offer comprises AU$20 million in senior unsecured zero-coupon convertible notes maturing in five years and AU$26 million worth of five-year unlisted warrants exercisable at AU$0.0494, the filing said.If the investor decides to convert the bonds into shares, its conversion value will be 25% above the immuno-oncology firm's closing price on Dec. 20, per the filing.Proceeds will be used to advance the company's azer-cel, onCARlytics, and Vaxinia trials, as per the filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","BK7508","IMU.AU"],"gpt_icon":0},{"id":"2493850027","title":"Imugene Ltd - Issuance of Convertible Notes & Warrants for up to a$46M","url":"https://stock-news.laohu8.com/highlight/detail?id=2493850027","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493850027?lang=en_us&edition=fundamental","pubTime":"2024-12-23 14:30","pubTimestamp":1734935401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NL1J1:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","BK7508","IMU.AU"],"gpt_icon":0},{"id":"2493786883","title":"Imugene - Capital Raised to Be Used to Fund Co's Ongoing Clinical Trial Pipeline Including Azer-Cel, Others","url":"https://stock-news.laohu8.com/highlight/detail?id=2493786883","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2493786883?lang=en_us&edition=fundamental","pubTime":"2024-12-23 14:30","pubTimestamp":1734935401,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241223:nFWN3NL1J1:2","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2492574871","title":"Imugene Ltd-Imugene Confirms Pending Receipt of C.$11M R&D Tax Refund","url":"https://stock-news.laohu8.com/highlight/detail?id=2492574871","media":"THOMSON REUTERS","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2492574871?lang=en_us&edition=fundamental","pubTime":"2024-12-19 05:54","pubTimestamp":1734558855,"startTime":"0","endTime":"0","summary":null,"market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://api.refinitiv.com/data/news/v1/stories/urn:newsml:reuters.com:20241218:nTUE7VNFSH:1","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"reuters_en_live","symbols":["BK7508","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2488952296","title":"6 ASX shares down 50%+ in 2024. Are they cheap?","url":"https://stock-news.laohu8.com/highlight/detail?id=2488952296","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2488952296?lang=en_us&edition=fundamental","pubTime":"2024-12-03 12:59","pubTimestamp":1733201940,"startTime":"0","endTime":"0","summary":"As most ASX investors would be aware, the stock market has had a very lucrative year over 2024 so far. As it currently stands, the S&P/ASX 200 Index (ASX: XJO) has gained a significant 11.6% or so ove","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/12/03/6-asx-shares-down-50-in-2024-are-they-cheap/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7049","BK7506","BK7078","BK7507","CTT.AU","SYR.AU","WC8.AU","XJO.AU","IMU.AU","BK7135","BK7508","CBA.AU","BK7095","SGR.AU","BK7021","SYA.AU","BK7067","BK7504"],"gpt_icon":0},{"id":"2482249519","title":"ASX Market Update: Index retreats as Chinese stimulus disappoints | November 11, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2482249519","media":"The Market Herald","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482249519?lang=en_us&edition=fundamental","pubTime":"2024-11-11 10:34","pubTimestamp":1731292440,"startTime":"0","endTime":"0","summary":"The ASX200 has been down 0.4% at 8,261 points.Investors reacted with disappointment to the latest Chinese stimulus measures released on the weekend. Declining iron ore and oil prices has adversely affected commodity stocks, as hopes of a strong uptick in Chinese driven demand were dashed.Materials has been the worst performer, down 2.4%, followed by Staples, down 1.7% and Energy, down 0.8%.Resoulute Mining  has been down 30% on news its CEO Terry Holohan and other company executives have been detained by the military controlled government of Mali in West Africa.Imugene has been up 4.4% on news its kicked off the injection phase of a trial of its innovative onCARlytics  candidate. This pivotal development marks the dosing of the first patient grappling with advanced solid tumours.Li-S Energy has been up 5.7% on reports it used a twelve-cell lithium sulfur battery pack to power a small UAV for 30 minutes. The fixed wing asset, which doesn’t use quadcopter style propellors and instead was","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-index-retreats-as-chinese-stimulus-disappoints-november-11-2024-2024-11-11/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["RSG.AU","BK7104","BK7508","LIS.AU","BK7023","IMU.AU","BK7067","BK7506"],"gpt_icon":0},{"id":"2482221089","title":"Imugene Doses First Patient in Intratumoral Injection Group of Phase 1 Cancer Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2482221089","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2482221089?lang=en_us&edition=fundamental","pubTime":"2024-11-11 09:42","pubTimestamp":1731289374,"startTime":"0","endTime":"0","summary":"Biotechnology company Imugene  said the first patient was dosed in the intratumoral combination group of phase 1 clinical trial on its oncolytic virotherapy candidate, CD19, according to a Monday filing with the Australian bourse.The study is part of the company's Oasis trial, which aims to evaluate the safety and efficacy of CD19 in patients with advanced or metastatic solid tumors, the filing said. It will explore the direct administration of CD19 into the tumor, as well as intravenous infusion.The trial is being conducted at seven US sites, with the potential to open a total of 10 sites to recruit up to 40 patients, according to the filing.","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2481711242","title":"Imugene Opens Australian Site for Phase 1b Lymphoma Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2481711242","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481711242?lang=en_us&edition=fundamental","pubTime":"2024-11-08 14:49","pubTimestamp":1731048579,"startTime":"0","endTime":"0","summary":"Imugene  opened its first Australian site for a phase 1b trial investigating the use of cell therapy azercabtagene zapreleucel as a potential treatment for patients with relapsed or diffused large-B lymphoma, according to a Friday filing with the Australian bourse.The US portion of the trial showed three patients having a complete response using the therapy, the filing said.Patient recruitment at the Australian site is slated for November, the filing added.The company's shares closed up more than 2% Friday.Price : $0.05, Change: $+0.001, Percent Change: +2.22%","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["BK4125","AUD","IMU.AU","LU0994945656.USD","XAO.AU","XKO.AU","LU0345774631.USD","BK7508","LU0426417589.USD","LU1043141123.HKD","LU2238339852.HKD","LU0426412945.USD","BK7067","XJO.AU"],"gpt_icon":0},{"id":"2481873167","title":"Why Imugene, Neuren, Sigma, and Smartgroup shares are charging higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2481873167","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481873167?lang=en_us&edition=fundamental","pubTime":"2024-11-08 10:13","pubTimestamp":1731032010,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index(ASX: XJO) is having a great finish to the week. In afternoon trade, the benchmark index is up 0.9% to 8,299.4 points. Four ASX shares that are rising more than most are listed bel","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/08/why-imugene-neuren-sigma-and-smartgroup-shares-are-charging-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["NEU.AU","SIQ.AU","XJO.AU","BK7508","BK7057","BK7096","BK7103","SIG.AU","IMU.AU","BK7067"],"gpt_icon":0},{"id":"2481698654","title":"Imugene Says Bile Tract Cancer Patient Remains in Complete Response for Over Two Years in Early-Stage Trial","url":"https://stock-news.laohu8.com/highlight/detail?id=2481698654","media":"MT Newswires Live","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481698654?lang=en_us&edition=fundamental","pubTime":"2024-11-06 09:14","pubTimestamp":1730855648,"startTime":"0","endTime":"0","summary":"Biotechnology company Imugene  said a bile tract cancer patient in its phase 1 metastatic advanced solid tumors trial for Vaxinia, a treatment candidate for bile tract cancer, remained in complete response, surpassing over two years in remission, according to a Tuesday filing with the Australian bourse.Meanwhile, the trial's bile tract cancer expansion phase cleared its first group, with the three patients experiencing no dose-limiting toxicities, and is now open for enrollment of up to 10 patients, the filing said.The company also secured a patent extension to 2040 from the US Patent and Trademark Office for patent application number 16/324,541, protecting its oncolytic virotherapy CF33, including Vaxinia and CHECKVacc, according to the filing.Imugene shares fell past 2% in morning trade Wednesday.Price : $0.05, Change: $-0.001, Percent Change: -2.13%","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.mtnewswires.com/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"mtnewswires_news","symbols":["AUD","IMU.AU","LU0426417589.USD","LU0994945656.USD","LU2238339852.HKD","BK7067","BK7508","LU0426412945.USD","BK4125","SSI","LU0345774631.USD","LU1043141123.HKD"],"gpt_icon":1},{"id":"2481175516","title":"Why Core Lithium, Imugene, Lifestyle Communities, and Mineral Resources shares are charging higher","url":"https://stock-news.laohu8.com/highlight/detail?id=2481175516","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481175516?lang=en_us&edition=fundamental","pubTime":"2024-11-05 11:54","pubTimestamp":1730778848,"startTime":"0","endTime":"0","summary":"TheS&P/ASX 200 Index (ASX: XJO) is out of form on Tuesday and dropping into the red. In afternoon trade, the benchmark index is down 0.4% to 8,132.7 points. Four ASX shares that are not letting that h","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/05/why-core-lithium-imugene-lifestyle-communities-and-mineral-resources-shares-are-charging-higher/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7508","BK7145","RIO.AU","MIN.AU","BK7511","BK7095","CXO.AU","BK7507","LTM.AU","BK7005","BK7067","BK7162","BK7036","IMU.AU","LIC.AU","XJO.AU","HMC.AU","BK7504","BK7062"],"gpt_icon":1},{"id":"2481856425","title":"Guess which ASX 300 stock is jumping 11% on big news","url":"https://stock-news.laohu8.com/highlight/detail?id=2481856425","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2481856425?lang=en_us&edition=fundamental","pubTime":"2024-11-05 07:28","pubTimestamp":1730762884,"startTime":"0","endTime":"0","summary":"Imugene Ltd  shares are having a strong start to the session on Tuesday. At the time of writing, the ASX 300 stock is up 11% to 4.9 cents. Why is this ASX 300 stock jumping?","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/11/05/guess-which-asx-300-stock-is-jumping-11-on-big-news/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["BK7067","IMU.AU","BK7508"],"gpt_icon":0},{"id":"2479482337","title":"ASX Market Update: Gina Rinehart buys permits from Min Res in billion dollar deal | October 31, 2024","url":"https://stock-news.laohu8.com/highlight/detail?id=2479482337","media":"The Market Herald","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479482337?lang=en_us&edition=fundamental","pubTime":"2024-10-31 11:17","pubTimestamp":1730344620,"startTime":"0","endTime":"0","summary":"The ASX200 has been down a third of a percent  at 8,154 points.Consumer Staples continue to be the worst performing sector, down 1.7%, with well-known plays Woolworths , Bega Cheese  and Elders  all dragging the local bourse lower. Utilities has been 1.2% softer, followed by Industrials, down 1%.IT has been the best performer, up 0.4%, followed by Discretionary, up 0.24% and Real Estate, up 0.15%.Imugene  has been down 4.3% on its quarterlies. The company reported cash or cash equivalents of $54.3 million, down from $93.1 million in the June quarter.Mineral Resources  has been up 11.3% on release of its quarterlies. The company has agreed to sell its two oil and gas exploration permits in the Perth Basin to Gina Rinehart’s Hancock Prospecting. Hancock will pay Mineral Res up to $1.1 billion for the permits.Coles  has been down 1.1% after releasing its quarterlies before market open. The company delivered a 2.9% increase in total sales to $10.54 billion for the three months ended 29 Sep","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://themarketonline.com.au/asx-market-update-gina-rinehart-buys-permits-from-min-res-in-billion-dollar-deal-october-31-2024-2024-10-31/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"markerherald_stock","symbols":["BK7095","ELD.AU","BK7082","BK7040","BK7117","BK7508","BGA.AU","BK7504","BK7141","BK7505","BK7511","WOW.AU","COL.AU","IMU.AU","BK7501","BK7067","MIN.AU","BK7507"],"gpt_icon":1},{"id":"2479523715","title":"2 All Ords ASX healthcare shares making BIG moves on quarterly updates","url":"https://stock-news.laohu8.com/highlight/detail?id=2479523715","media":"MotleyFool","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2479523715?lang=en_us&edition=fundamental","pubTime":"2024-10-31 09:39","pubTimestamp":1730338765,"startTime":"0","endTime":"0","summary":"Paradigm share price lifts off on trial progress The Paradigm Biopharmaceuticals Ltd  share price is up 2.5% at the time of writing, having earlier posted gains of 17.5%. Shares are currently changing hands for 20.5 cents apiece. That leaves the All Ords ASX healthcare share down 51% since this time last year. Investors have been bidding up the Paradigm share price after the company reported on the \"substantial progress\" it made over the quarter in its Phase 3 clinical trial preparations for the treatment of knee osteoarthritis with its iPPS product. Commenting on the recent achievements, Paradigm Biopharmaceuticals managing director Paul Rennie said, \"The submission of our phase 3 protocol to the FDA is a significant milestone for Paradigm.\" Rennie continued:  It represents the culmination of extensive work by our team and close collaboration with the FDA. We are confident that this progress, combined with the anticipated TGA [Therapeutic Goods Administration] response and our ongoing","market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"en","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.fool.com.au/2024/10/31/2-all-ords-asx-healthcare-shares-making-big-moves-on-quarterly-updates/","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"motleyfoolau_stock","symbols":["IMU.AU","XAO.AU","BIG","BK7067","PAR.AU","BK7508","XJO.AU","BK4220","BK4114"],"gpt_icon":0}],"pageSize":16,"totalPage":4,"pageCount":3,"totalSize":50}]}}